Wall Street brokerages forecast that Can-Fite Biopharma Ltd (NASDAQ:CANF) will report earnings per share of ($0.80) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Can-Fite Biopharma’s earnings. Can-Fite Biopharma reported earnings of ($0.90) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 11.1%. The business is expected to issue its next quarterly earnings report on Friday, August 30th.

According to Zacks, analysts expect that Can-Fite Biopharma will report full year earnings of ($1.49) per share for the current fiscal year. For the next financial year, analysts anticipate that the firm will report earnings of ($0.32) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Can-Fite Biopharma.

Can-Fite Biopharma (NASDAQ:CANF) last issued its quarterly earnings results on Wednesday, May 29th. The company reported ($1.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.94) by $0.74. The business had revenue of $0.30 million for the quarter.

Separately, HC Wainwright reiterated a “buy” rating on shares of Can-Fite Biopharma in a report on Tuesday, March 26th.

Can-Fite Biopharma stock traded up $0.04 during mid-day trading on Tuesday, reaching $2.83. 11,400 shares of the company’s stock were exchanged, compared to its average volume of 129,984. The business has a fifty day simple moving average of $3.42. Can-Fite Biopharma has a one year low of $2.66 and a one year high of $25.95.

About Can-Fite Biopharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Further Reading: What is a stock buyback?

Get a free copy of the Zacks research report on Can-Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.